Key Highlights

  • 9.27% was the gain in the traded price of Entrada Therapeutics, Inc. (NASDAQ:TRDA), which reached USD 5.42 on November 18, 2026 from a calculated prior close of USD 4.96, on Volume of 56.48K shares.
  • 193.0 in USD millions was cash, cash equivalents and marketable securities at September 30, 2026, down from USD 295.7 million at December 31, 2025, with runway expected into the fourth quarter of 2027.
  • 39.7 in USD millions was the third quarter 2026 net loss, or USD 0.94 per share, narrowing from a USD 44.1 million loss in the third quarter of 2025.
  • 4 clinical readouts are expected through the first half of 2027, including ELEVATE-44-201 cohort 1 data by year-end 2026 and cohort 2 data in the first quarter of 2027.

What Moved Entrada Therapeutics, Inc. (NASDAQ:TRDA) in Trading on November 18, 2026 (+USD 0.46, +9.27%)

Entrada Therapeutics, Inc. traded at USD 5.42 in the November 18, 2026 session, a gain of 9.27%. The calculated prior close was USD 4.96, so the calculated move was +USD 0.46 per share. The stock opened 0.40% below the prior close, a calculated opening level of about USD 4.94, and then traded 9.72% above the open, so the entire advance came after the opening bell. Volume reached 56.48K shares, a thin count. A corroborated market Capitalization was not available, so no Market Value is stated here.

The Rationale: Clinical Readout Anticipation for Entrada Therapeutics, Inc. (NASDAQ:TRDA)

No company-specific catalyst dated November 18, 2026 was identified in published coverage. As general context, thinly traded biotech shares can move sharply on modest buying, and approaching data events often draw positioning. The most recent reported period is the third quarter of 2026, released on November 5, 2026. Collaboration Revenue was USD 0.9 million against USD 1.6 million a year earlier. Research and Development expense fell to USD 32.4 million from USD 38.4 million, and general and administrative expense was USD 10.2 million. ELEVATE-45-201 cohort 1 data in October 2026 met its primary safety and tolerability objective, and ENTR-601-45 received FDA Orphan Drug designation for Duchenne muscular dystrophy that month.

Valuation, Liquidity and Risks for Entrada Therapeutics, Inc. (NASDAQ:TRDA)

Entrada reported a net loss of USD 39.7 million, or USD 0.94 per share, on weighted-average shares of 42,373,345. Cash of USD 193.0 million equals about USD 4.55 per weighted-average share (calculated), compared with the calculated prior close of USD 4.96. The cash balance fell by a calculated USD 102.7 million since December 31, 2025. Revenue is small, so the valuation rests on pipeline outcomes rather than earnings. Risks include clinical and safety results, dependence on partnered programs such as VX-670 with Vertex, continuing losses, future financing and dilution, and thin liquidity.

Where Things Stand

Entrada Therapeutics, Inc. (NASDAQ:TRDA) advanced 9.27% to USD 5.42 on November 18, 2026, from a calculated prior close of USD 4.96, after opening 0.40% lower and gaining 9.72% from the open. Volume was 56.48K shares. No catalyst for the session was identified in published coverage. The latest results, for the third quarter of 2026 and released November 5, 2026, showed collaboration revenue of USD 0.9 million, a net loss of USD 39.7 million and cash of USD 193.0 million. Cohort 1 data from ELEVATE-44-201 are expected by year-end 2026. Share prices of clinical-stage companies can move sharply around such readouts in either direction, and light volume can magnify moves.